|
|
||||||||||
|
J Am Coll Cardiol, 2006; 47:44-49, doi:10.1016/j.jacc.2005.10.023 © 2006 by the American College of Cardiology Foundation |




* Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida
Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Atlanta Cardiovascular Research Institute, Atlanta, Georgia
|| Division of Cardiology, Department of Medicine, Cedars-Sinai Research Institute, Cedars-Sinai Medical Center, Los Angeles, California
¶ Division of Cardiology, Rhode Island Hospital, Providence, Rhode Island
# Division of Heart and Vascular Disease, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
Manuscript received September 28, 2004; revised manuscript received January 11, 2005, accepted January 17, 2005.
* Reprint requests and correspondence: Dr. Eileen Handberg, Division of Cardiovascular Medicine, University of Florida College of Medicine, P.O. Box 100277, Gainesville, Florida 32610-0277 (Email: handbem{at}medicine.ufl.edu).
| Abstract |
|---|
|
|
|---|
BACKGROUND: Reduced functional capacity and impaired vascular reactivity are associated with poor prognosis, but an association between vascular reactivity and functional capacity is unknown.
METHODS: A total of 190 women enrolled in the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Womens Ischemia Syndrome Evaluation (WISE) study had baseline clinical assessment and coronary artery flow velocity response to adenosine (CFVRado). We compared these results with self-reported DASI metabolic equivalents (METs).
RESULTS: Mean age was 55 ± 11 years (range 21 to 83 years), and only 18% had coronary stenosis
50%. Women with a CFVRado <2.5 (n = 98) had mean DASI of 15.1 ± 13.6, compared to women (n = 92) with CFVRado
2.5, whose mean DASI was 21.0 ± 15.2 (p = 0.004). This relationship was maintained after adjusting for age and presence of coronary artery disease. CFVRado of
2.5 was associated with a DASI of >20 (odds ratio 3.03, 95% confidence interval 1.56 to 5.90, p = 0.001).
CONCLUSIONS: Women with reduced CFVRado were significantly more likely to have reduced functional capacity. Impairment in coronary vascular function and reduced levels of activity may both play a role in the poorer prognosis observed in the WISE study women; however, the relationship between the two is still unclear.
| |||||||||
| Methods |
|---|
|
|
|---|
Baseline evaluation. Baseline evaluation consisted of a physical exam and collection of clinical data, including the DASI questionnaire. Demographic, clinical, and angiographic data were collected at the WISE study data coordinating center in Pittsburgh, Pennsylvania. Qualitative and quantitative coronary angiographic analyses were carried out by a core laboratory (Rhode Island Hospital, Providence, Rhode Island) according to methodology and definitions previously published from the WISE study (11). We defined any angiographic stenosis of >50% of luminal diameter as significant CAD. The CAD severity score was derived as an aggregate of percentage of luminal stenosis, extent and location of stenosis, and degree of collateral vessels (11).
Measurement of functional capacity. The DASI is a score derived from a 12-item self-reported questionnaire that captures a persons ability to perform various routine activities. These activities have been shown to accurately estimate peak oxygen consumption (5,6). By dividing the DASI score by 3.5, MET levels were derived. Women with a DASI score of <20, which corresponds to 5.7 METs, were considered functionally impaired (12).
Measurement of coronary microvascular function. To assess coronary vascular function, testing was performed in a left coronary artery branch (left anterior descending coronary artery [n = 137] or circumflex coronary artery [n = 53]) without obstructive atherosclerosis (diameter stenosis <50%) after vasoactive medications had been withdrawn for at least 48 h. To assess blood flow velocity reserve, a Doppler-tipped guidewire (0.014-inch FloWire; Jomed/Cardiometrics, Mountain View, California) was advanced through the diagnostic catheter, and recordings were made once a stable Doppler signal in the proximal or mid vessel was obtained. Intracoronary bolus injections of 18 µg adenosine (Adenocard; Fujisawa USA, Deerfield, Illinois) were administered into the left main coronary artery. The coronary flow velocity increase resulting from dilation of the microvasculature was measured (11). A CFVRado of <2.5 was taken to represent impaired coronary vascular function. (13).
Statistical analysis.
The primary analysis in this report is the relationship between functional capacity as assessed by DASI scores and a measure of coronary reactivity using CFVRado. The relationships among these measurements and other demographic and CAD risk factor variables were also investigated. For comparing women with normal (CFVRado
2.5) versus impaired (CFVRado <2.5) coronary reactivity, and normal (DASI
20) versus impaired (DASI <20) functional capacity, unadjusted means ± standard deviations or frequencies (%) were calculated. We also used tertile analysis to examine the gradient between high, medium, and low CFVRado and high, medium, and low DASI in this study population. The Mantel-Haenszel chi square was used to evaluate the p value for trend. Because demographic and/or clinical data tend to have skewed distributions, we used Wilcoxon rank sum tests to compare continuous variables, chi square tests to compare categorical variables, and Spearman rank correlations to describe the relationship between continuous variables. Logistic regression analysis was used to adjust these for age and CAD. Stepwise logistic regression analysis was used to model normal versus low functional capacity as a function of coronary reactivity and other coronary risk factors. Variables considered for inclusion in the model included the baseline characteristics listed in Tables 1 and 2,
and variables were then chosen for entry into multivariable models based upon univariate associations of p
0.10. In order to account for possible modulator effects, we then forced all other variables from Tables 1 and 2 into the models, one at a time. Summary statistics for the regression models included the c-statistic (a measure of association of predicted probabilities and observed prevalence of a binary outcome) and R2 (re-scaled for use in logistic regression). For all analyses, a two-tailed p value of <0.05 was considered statistically significant.
|
|
| Results |
|---|
|
|
|---|
30 kg/m2) and had hypertension or dyslipidemia. Seventy percent of the WISE study women had a family member with premature heart disease. Twenty percent had a history of diabetes mellitus, currently smoked, or had significant angiographic CAD. Somewhat more than half of the women had an impaired CFVRado (<2.5). This population was also characterized by impaired functional capacity, with a mean DASI of 18.0 ± 14.6 (equivalent to 5.1 METS), and two-thirds having a DASI of <20. Only 10% indicated that they could participate without difficulty in strenuous sports, which included swimming (question 12 in the DASI). Women with impaired CFVRado were significantly older, had higher systolic blood pressure, pulse pressure, and beta-blocker use, and more frequently had impaired functional capacity. No other laboratory values or medication use were significantly different. The differences between women with normal and impaired CFVRado persisted even after adjusting for age and presence of CAD (Table 1). Baseline characteristics of the women categorized by impaired versus normal functional capacity (DASI <20 vs. >20) are summarized in Table 2. The group with impaired functional capacity had significantly lower CFVRado compared to the group with normal functional capacity (2.4 ± 0.7 vs. 2.7 ± 0.7; p = 0.004). Women with impaired functional capacity also had significantly higher CAD severity scores, and a higher proportion had significant CAD (24% vs. 8%; p = 0.007). Use of aspirin, calcium antagonists, and nitrates was seen in significantly higher percentages of women with impaired functional capacity compared to those with normal functional capacity. After adjusting for age and presence of CAD, only normal CFVRado (p = 0.01), and nitrate use (p = 0.01) remained significantly predictive. The presence and severity of CAD also remained significant after adjustment for age.
The Spearman rank correlation between DASI and CFVRado was 0.20 (p = 0.005). Figure 1 characterizes the women by tertiles for both DASI and CFVRado. For each increasing tertile of CFVR, a higher proportion of women had normal functional capacity and a decreasing proportion of women had low functional capacity (p for trend = 0.02).
|
2.5 (odds ratio [OR] 3.03, 95% confidence interval [CI] 1.56 to 5.90; p = 0.001), CAD severity score (OR 0.92, 95% CI 0.85 to 0.99; p = 0.04), and diastolic blood pressure (OR 1.03, 95% CI 1.001 to 1.07; p = 0.04) (Table 3). Substituting presence/absence of obstructive CAD did not greatly affect the model, although nitrate use entered as a significant covariate. Similarly, limiting the analysis to only those without CAD did not change the model. To exclude the modulating effect of other variables, we added each variable from Tables 1 and 2 in turn to the models. These were not independent predictors of functional capacity, nor did their addition to the model affect the robust relationship between CFVRado and DASI.
|
| Discussion |
|---|
|
|
|---|
Exercise capacity has been shown to be an important prognostic predictor in patients with cardiovascular disease. In a study involving more than 6,000 men who underwent clinically indicated exercise electrocardiogram treadmill, a low metabolic equivalent was associated with mortality (1). Peak exercise capacity measured by METs was the strongest predictor of death in patients with cardiovascular disease and also in normal subjects (14). Exercise capacity was a stronger predictor of mortality than traditional risk factors for cardiovascular disease. Furthermore, in patients with heart failure, decreased functional capacity has been shown to be associated with worse cardiovascular outcomes (15). In addition to the high-risk patient groups, impaired exercise capacity has been shown to correlate with cardiovascular death in asymptomatic men (1). In a recent analysis from the Women Take Heart project, exercise capacity was found to be a strong independent predictor of all-cause death in asymptomatic women as well (2). This relationship held even after adjusting for traditional cardiac risk factors. For each MET increase in exercise capacity, a 17% reduction in mortality rate was seen. More recent WISE study data have shown that lower functional capacity, assessed by DASI, was associated with higher prevalence of coronary heart disease risk factors and angiographic CAD at baseline and associated with higher risk of adverse events during intermediate follow-up and was independent of both traditional cardiovascular risk factors and anthropometric measurements (9).
The exact mechanisms responsible for this observed relationship are unclear. In our study, impaired overall functional capacity was independently associated with coronary microvascular dysfunction. Impaired vascular function is believed to be integral to the formation of atherosclerotic heart disease. The identification of endothelial dysfunction in the absence of significant occlusive disease presents a global pattern of dysfunction in the macro- and microcirculation and has been postulated to represent one of the earliest manifestations of atherosclerosis (16). Impaired vascular function has been shown to be independently associated with adverse cardiovascular outcomes in the absence of epicardial coronary disease (17). This is the first study to demonstrate that nonendothelial-dependent microvascular dysfunction is associated with decreased functional capacity in women. Decreased functional capacity in the WISE study women has been recently shown to be correlated with adverse outcome (9). Disordered vascular smooth muscle and endothelial interactions may contribute to the ability of the coronary vessels to respond to changes in perfusion pressure and metabolic demands during ischemia and infarction. This and other nonatherosclerotic mechanisms could contribute to the decreased functional capacity and poor outcomes observed in women with ischemic heart disease.
Interventions targeting decreased functional capacity have resulted in improvements in both symptoms and measures of microvascular function. Eriksson et al. (18) compared an eight-week exercise training program to a control group in patients with syndrome X. The exercise training resulted in a significant increase in exercise capacity with less anginal pain. There was a trend toward an endothelium-dependent blood flow increases after training (p = 0.06). Recent work by Woo et al. (19) suggests improvements in arterial endothelial function after six weeks to one year of diet versus diet and exercise in a group of 82 obese but otherwise healthy children. At one year, there was significantly less carotid intimal thickening in the group that continued to diet and exercise and sustained improvement in arterial endothelial function. Data from Hambrecht et al. (20) have demonstrated that impairment in coronary artery endothelial function could be reversed by a short-term moderate level of exercise training. Our data, which demonstrates that increasing levels of functional capacity are associated with increases in CFVRado, would support the hypothesis that if vascular dysfunction is reversible, an intervention that increases functional capacity should increase vascular function. Hambrecht et al. (20) also observed that exercise training resulted in improvements in agonist-mediated endothelium-dependent vasodilatory capacity of the left internal mammary artery in patients with CAD. There was a significant increase in endothelial nitric oxide synthase protein expression in the training group compared with the control group. We have observed that hemoglobin levels show an association with DASI scores, vascular reactivity, and adverse cardiovascular outcomes in the WISE study population (21). Thus we could postulate a possible interaction among nitric oxide metabolism, hemoglobin levels, and impaired microvascular function (22), which all ultimately may contribute to reduced functional capacity and worsened cardiovascular outcome. This interaction also opens another possible therapeutic target for future studies.
The American Heart Association has expressed the need to find noninvasive screening tests that predict cardiac risk (23). In women, the need for better risk stratification is extremely important, given the gender-related diagnostic dilemmas. Because, as shown here, lower DASI scores correlate with impaired coronary vascular function and elsewhere with higher risk for adverse outcomes, the DASI may be a simple and easy to use tool that contributes to the global risk assessment. This instrument is easy to use and cheap and needs further study to confirm our findings.
Study limitations. Our study evaluated a relatively small group of women with chest pain and ischemic-type symptoms warranting referral for coronary angiography, which may lead to a referral bias and limited generalization of the results. We measured coronary vascular response at only one point in time, so unknown or unmeasurable factors could potentially alter the responses at that point in time. Our cross-sectional design precludes inferring a causal relationship between vascular reactivity and functional capacity.
Conclusions. Women with reduced CFVRado were significantly more likely to have reduced functional capacity as assessed by the DASI. The DASI may offer a simple noninvasive measure of global cardiovascular risk that is linked to impairment in coronary vascular function.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF] |
||||
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF] |
||||
![]() |
L. M Gruen and C. J Pepine Raising awareness of angina in women Heart, March 1, 2007; 93(3): 279 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
Coronary Vascular Reactivity and Functional Capacity Journal Watch Women's Health, April 18, 2006; 2006(418): 7 - 7. [Full Text] |
||||
![]() |
C. J. Pepine Ischemic Heart Disease in Women J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S1 - S3. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |